… Read More
Foldax® announced today that it has been selected as Company of the Year among 10 cardiovascular device company finalists by MedTech Outlook Magazine. Foldax was honored for its innovative Tria™ heart valve, the first biopolymer heart valve to receive FDA approval for a U.S. clinical trial.
Foldax has reinvented every aspect of the artificial heart valve – from material to design to manufacturing – to develop surgical and transcatheter valves designed to last a lifetime that address historical tradeoffs. The Tria heart valve is made with its proprietary LifePolymer™ biopolymer that, combined with an innovative valve design, is intended to eliminate calcification, withstand stresses and strains in the heart without failure, and restore patient quality of life without lifelong anticoagulant use.
Tria is also the first and only heart valve to be robotically manufactured, reducing variability and enabling high precision, repeatability and quality, while substantially improving the economics of heart
… Read More
The Nano-Bio Materials Consortium (NBMC), led by the Air Force Research Laboratory (AFRL) in partnership with SEMI, have publicly released a Request for Proposals (RFP) for dual-use projects designed to accelerate Smart MedTech innovations in health monitoring, diagnostics and performance augmentation. AFRL has provided primary funding for the approximate $7 million fiscal year 2021 call for projects as part of its mission to address key capability and technology gaps in support of human performance monitoring and aeromedical evacuation.
NBMC was founded in 2013 to bring together scientists, engineers and business development professionals from industry, government and universities to collaborate in research and development. To date, NBMC has funded 26 separate projects, with more than 24 organizational participants. They have developed materials, electronics, microfluidics, manufacturing processes and algorithms to create low-cost, wearable sensors. Most of these integrated sensing systems communicate wirelessly, are flexible, and incorporate high-performance silicon devices that are
… Read More
HOUSTON and VANCOUVER, BC, Sept. 21, 2020 /PRNewswire/ – ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI; ) (“ESSA” or the “Company”), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22nd at 11:40am Eastern
Dr. David. R. Parkinson, Chief Executive Officer, will present a corporate overview of the Company’s business. Dr. Parkinson along with ESSA’s Chief Operating Officer, Peter Virsik, and Chief Financial Officer, David S. Wood will be available for one-on-one meetings.
The presentations will be webcast live and can be accessed through the Investor Relations page at www.essapharma.com. A replay of the presentations will be available on the Company’s website for 90 days.
Tuesday September 22, 2020
Presentation Date: Tuesday September 22, 2020
Presentation Time: 8:40am Pacific / 11:40am Eastern